University of Sussex
Browse
e232502.full.pdf (221.31 kB)

Low-dose naltrexone as a treatment for chronic fatigue syndrome

Download (221.31 kB)
Version 2 2023-06-12, 08:06
Version 1 2023-06-10, 01:11
journal contribution
posted on 2023-06-12, 08:06 authored by Monica Jane Bolton, Bryan Paul Chapman, Harm van MarwijkHarm van Marwijk
Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. Although only small-scale clinical trials have been performed, these suggest efficacy in several diseases including Crohn’s disease, fibromyalgia and Gulf War Illness. Despite numerous internet reports of response to low-dose naltrexone (LDN), no clinical trials exist in people with chronic fatigue syndrome. This condition is characterised by chronic profound fatigue, postexertional malaise, pain and autonomic and neurocognitive disturbances. This series of three case reports compiled by people with long-term ill-health due to chronic fatigue syndrome shows the range of responses they observed when taking LDN, from life changing to a reduction in some symptoms only. Treatment doses ranged from 4 to 12?mg. Clinical trials may be warranted to explore the potential use of naltrexone in people with these debilitating illnesses which currently have no licensed treatments available.

History

Publication status

  • Published

File Version

  • Published version

Journal

BMJ Case Reports

ISSN

1757-790X

Publisher

BMJ Publishing Group

Volume

13

Page range

1-5

Article number

a232502

Event location

England

Department affiliated with

  • Primary Care and Public Health Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2021-09-29

First Open Access (FOA) Date

2021-09-29

First Compliant Deposit (FCD) Date

2021-09-28

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC